Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 and Bicalutamide in CRPC
NCT00630344Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in castration-resistant prostate cancer (CRPC), sponsored by Dana-Farber Cancer Institute. Started Feb 2008; status: completed.
02
Drugs
everolimus
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00630344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630344.